Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1723-1736

  Smith, Daniel J ^a,b,c   Lamont, Iain L ^d   Anderson, Greg J ^c   Reid, David W ^a,b,c  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GALLIUM; GALLIUM NITRATE; IRON CHELATING AGENT; LACTOFERRIN; LACTOFERRIN PLUS HYPOTHIOCYANATE; MEVEOL; PENICILLIN SIDEROPHORE CONJUGATE; PYOCHELIN; PYOVERDINE; SIDEROPHORE; UNCLASSIFIED DRUG;

BIOFILM; CYSTIC FIBROSIS; DRUG CONJUGATION; DRUG TARGETING; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; IRON METABOLISM; IRON TRANSPORT; MEMBRANE FORMATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; TRANSLATIONAL RESEARCH;

ANTI-INFECTIVE AGENTS; BIOFILMS; CHELATING AGENTS; CYSTIC FIBROSIS; GENE EXPRESSION REGULATION, BACTERIAL; HOMEOSTASIS; HUMANS; IRON; LACTOFERRIN; LUNG; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; RESPIRATORY TRACT INFECTIONS; THIOCYANATES;

EID: 84890091539     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00124012     Document Type: Review

References (110)

1. Kobayashi H, Kobayashi O, Kawai S. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract. J Infect Chemother 2009; 15: 125-142.
2. Rau MH, Hansen SK, Johansen HK, et al. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 2010; 12: 1643-1658.
3. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-964.
4. Trautmann M, Lepper PM, Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am J Infect Control 2005; 33: S41-S49.
5. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns 2002; 28: 340-348.
6. Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15: 138-142.
7. Vasil ML, Ochsner UA. The response of Pseudomonas aeruginosa to iron: genetics, biochemistry and virulence. Mol Microbiol 1999; 34: 399-413.
8. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005-1015.
9. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487: 109-113.
10. Tate S, MacGregor G, Davis M, et al. Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax 2002; 57: 926-929.
11. Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 174-183.
12. Moreau-Marquis S, Bomberger JM, Anderson GG, et al. The ΔF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L25-L37.
13. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109: 317-325.
14. Sanderson K, Wescombe L, Kirov SM, et al. Bacterial cyanogenesis occurs in the cystic fibrosis lung. Eur Respir J 2008; 32: 329-333.
15. King P, Citron DM, Griffith DC, et al. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis 2010; 66: 181-186.
16. Ranganathan SC, Parsons F, Gangell C, et al. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011; 66: 408-413.
17. Cystic Fibrosis Foundation. Patient Registry 2010: Annual Data Report. Bethesda, USA, 2012.
18. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995-1001.
19. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
20. Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax 2011; 66: 558-559.
21. Tunney MM, Klem ER, Fodor AA, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011; 66: 579-584.
22. Valavanidis A, Fiotakis K, Vlachogianni T. Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008; 26: 339-362.
23. Cole AM, Waring AJ. The role of defensins in lung biology and therapy. Am J Respir Med 2002; 1: 249-259.
24. Stites SW, Plautz MW, Bailey K, et al. Increased concentrations of iron and isoferritins in the lower respiratory tract of patients with stable cystic fibrosis. Am J Respir Crit Care Med 1999; 160: 796-801.
25. Reid DW, Lam QT, Schneider H, et al. Airway iron and iron-regulatory cytokines in cystic fibrosis. Eur Respir J 2004; 24: 286-291.
26. Stites SW, Walters B, O'Brien-Ladner AR, et al. Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis. Chest 1998; 114: 814-819.
27. Gifford AH, Miller SD, Jackson BP, et al. Iron and CF-related anemia: expanding clinical and biochemical relationships. Pediatr Pulmonol 2011; 46: 160-165.
28. Reid DW, Carroll V, O'May C, et al. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J 2007; 30: 286-292.
29. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-921.
30. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72: 2064-2069.
31. Eichler I, Nilsson M, Rath R, et al. Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J 1999; 14: 1145-1149.
32. Hassett DJ, Korfhagen TR, Irvin RT, et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 2010; 14: 117-130.
33. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44: 547-558.
34. Klausen M, Heydorn A, Ragas P, et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol 2003; 48: 1511-1124.
35. Klausen M, Aaes-Jorgensen A, Molin S, et al. Involvement of bacterial migration in the development of complex multicellular structures in Pseudomonas aeruginosa biofilms. Mol Microbiol 2003; 50: 61-68.
36. Banin E, Vasil ML, Greenberg EP. Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA 2005; 102: 11076-11081.
37. Chen X, Stewart PS. Role of electrostatic interactions in cohesion of bacterial biofilms. Appl Microbiol Biotechnol 2002; 59: 718-720.
38. Bollinger N, Hassett DJ, Iglewski BH, et al. Gene expression in Pseudomonas aeruginosa: evidence of iron override effects on quorum sensing and biofilm-specific gene regulation. J Bacteriol 2001; 183: 1990-1996.
39. Duan K, Surette MG. Environmental regulation of Pseudomonas aeruginosa PAO1 Las and Rhl quorum-sensing systems. J Bacteriol 2007; 189: 4827-4836.
40. Oglesby AG, Farrow JM 3rd, Lee JH, et al. The influence of iron on Pseudomonas aeruginosa physiology: a regulatory link between iron and quorum sensing. J Biol Chem 2008; 283: 15558-15567.
41. Diggle SP, Matthijs S, Wright VJ, et al. The Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. Chem Biol 2007; 14: 87-96.
42. Bredenbruch F, Geffers R, Nimtz M, et al. The Pseudomonas aeruginosa quinolone signal (PQS) has an ironchelating activity. Environ Microbiol 2006; 8: 1318-1329.
43. Davey ME, Caiazza NC, O'Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 2003; 185: 1027-1036.
44. Glick R, Gilmour C, Tremblay J, et al. Increase in rhamnolipid synthesis under iron-limiting conditions influences surface motility and biofilm formation in Pseudomonas aeruginosa. J Bacteriol 2010; 192: 2973-2980.
45. Schooling S, Charaf UK, Allison DG, Gilbert P. A role for rhamnolipid in biofilm dispersion. Biofilms 2004; 1: 90-99.
46. Patriquin GM, Banin E, Gilmour C, et al. Influence of quorum sensing and iron on twitching motility and biofilm formation in Pseudomonas aeruginosa. J Bacteriol 2008; 190: 662-671.
47. Yang L, Barken KB, Skindersoe ME, et al. Effects of iron on DNA release and biofilm development by Pseudomonas aeruginosa. Microbiology 2007; 153: 1318-1328.
48. Musk DJ, Banko DA, Hergenrother PJ. Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem Biol 2005; 12: 789-796.
49. Ochsner UA, Johnson Z, Vasil ML. Genetics and regulation of two distinct haem-uptake systems, Phu and Has, in Pseudomonas aeruginosa. Microbiology 2000; 146: 185-198.
50. Letoffe S, Redeker V, Wandersman C. Isolation and characterization of an extracellular haem-binding protein from Pseudomonas aeruginosa that shares function and sequence similarities with the Serratia marcescens HasA haemophore. Mol Microbiol 1998; 28: 1223-1234.
51. Alontaga AY, Rodriguez JC, Schonbrunn E, et al. Structural characterization of the hemophore HasAp from Pseudomonas aeruginosa: NMR spectroscopy reveals protein-protein interactions between Holo-HasAp and hemoglobin. Biochemistry 2009; 48: 96-109.
52. Cornelis P. Iron uptake and metabolism in pseudomonads. Appl Microbiol Biotechnol 2010; 86: 1637-1645.
53. Lamont IL, Konings AF, Reid DW. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. Biometals 2009; 22: 53-60.
54. Visca P, Imperi F, Lamont IL. Pyoverdine siderophores: from biogenesis to biosignificance. Trends Microbiol 2007; 15: 22-30.
55. Meyer JM, Stintzi A, De Vos D, et al. Use of siderophores to type pseudomonads: the three Pseudomonas aeruginosa pyoverdine systems. Microbiology 1997; 143: 35-43.
56. Marshall B, Stintzi A, Gilmour C, et al. Citrate-mediated iron uptake in Pseudomonas aeruginosa: involvement of the citrate-inducible FecA receptor and the FeoB ferrous iron transporter. Microbiology 2009; 155: 305-315.
57. Cornelis P, Matthijs S, Van Oeffelen L. Iron uptake regulation in Pseudomonas aeruginosa. Biometals 2009; 22: 15-22.
58. Prince RW, Cox CD, Vasil ML. Coordinate regulation of siderophore and exotoxin A production: molecular cloning and sequencing of the Pseudomonas aeruginosa fur gene. J Bacteriol 1993; 175: 2589-2598.
59. Wilderman PJ, Sowa NA, FitzGerald DJ, et al. Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis. Proc Natl Acad Sci USA 2004; 101: 9792-9797.
60. Vasil ML. How we learnt about iron acquisition in Pseudomonas aeruginosa: a series of very fortunate events. Biometals 2007; 20: 587-601.
61. Musk DJ Jr, Hergenrother PJ. Chelated iron sources are inhibitors of Pseudomonas aeruginosa biofilms and distribute efficiently in an in vitro model of drug delivery to the human lung. J Appl Microbiol 2008; 105: 380-388.
62. Le BV, Khorsi-Cauet H, Bach V, et al. Modulation of Pseudomonas aeruginosa lipopolysaccharide-induced lung inflammation by chronic iron overload in rat. FEMS Immunol Med Microbiol 2012; 64: 255-264.
63. Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys Acta 2009; 1790: 731-739.
64. Chitambar CR, Narasimhan J. Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 1991; 59: 3-10.
65. Kaneko Y, Thoendel M, Olakanmi O, et al. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007; 117: 877-888.
66. DeLeon K, Balldin F, Watters C, et al. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob Agents Chemother 2009; 53: 1331-1337.
67. Banin E, Lozinski A, Brady KM, et al. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc Natl Acad Sci USA 2008; 105: 16761-16766.
68. Chitambar CR. Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 2010; 7: 2337-2361.
69. Adamcakova-Dodd A, Magwood J, Kim J, et al. Toxicity assessment of gallium nitrate inhalation using murine model. American Thoracic Society Annual Scientific Meeting. May 19, 2010, New Orleans. Am J Respir Crit Care Med 2010; 181: A6266.
70. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002; 109: 693-697.
71. Valenti P, Berlutti F, Conte MP, et al. Lactoferrin functions: current status and perspectives. J Clin Gastroenter 2004; 38: S127-S129.
72. Rogan MP, Taggart CC, Greene CM, et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004; 190: 1245-1253.
73. O'May CY, Sanderson K, Roddam LF, et al. Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. J Med Microbiol 2009; 58: 765-773.
74. Ammons MC, Ward LS, Dowd S, et al. Combined treatment of Pseudomonas aeruginosa biofilm with lactoferrin and xylitol inhibits the ability of bacteria to respond to damage resulting from lactoferrin iron chelation. Int J Antimicrob Agents 2011; 37: 316-323.
75. Singh PK. Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 2004; 17: 267-270.
76. Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 2009; 41: 305-313.
77. Liu Y, Yang L, Molin S. Synergistic activities of an efflux pump inhibitor and iron chelators against Pseudomonas aeruginosa growth and biofilm formation. Antimicrob Agents Chemother 2010; 54: 3960-3963.
78. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010; 65: 2382-2395.
79. Braun V, Braun M. Active transport of iron and siderophore antibiotics. Curr Opin Microbiol 2002; 5: 194-201.
80. Budzikiewicz H. Siderophore-antibiotic conjugates used as Trojan horses against Pseudomonas aeruginosa. Curr Top Med Chem 2001; 1: 73-82.
81. Pramanik A, Stroeher UH, Krejci J, et al. Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae. Int J Med Microbiol 2007; 297: 459-469.
82. Braun V, Pramanik A, Gwinner T, et al. Sideromycins: tools and antibiotics. Biometals 2009; 22: 3-13.
83. Mollmann U, Heinisch L, Bauernfeind A, et al. Siderophores as drug delivery agents: application of the "Trojan horse" strategy. Biometals 2009; 22: 615-624.
84. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 2010; 54: 2291-2302.
85. Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007; 71: 413-451.
86. Wade WF, O'Toole GA. Antibodies and immune effectors: shaping Gram-negative bacterial phenotypes. Trends Microbiol 2010; 18: 234-239.
87. Ferreras JA, Ryu JS, Di Lello F, et al. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nature Chem Biol 2005; 1: 29-32.
88. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008; 4: CD001399.
89. Kamei A, Coutinho-Sledge YS, Goldberg JB, et al. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun 2011; 79: 1289-1299.
90. Alteri CJ, Hagan EC, Sivick KE, et al. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathogens 2009; 5: e1000586.
91. Shand GH, Pedersen SS, Brown MR, et al. Serum antibodies to Pseudomonas aeruginosa outer-membrane proteins and iron-regulated membrane proteins at different stages of chronic cystic fibrosis lung infection. J Med Microbiol 1991; 34: 203-212.
92. Coenye T. Social interactions in the Burkholderia cepacia complex: biofilms and quorum sensing. Future Microbiol 2010; 5: 1087-1099.
93. Starner TD, Zhang N, Kim G, et al. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 213-220.
94. Yang L, Liu Y, Markussen T, et al. Pattern differentiation in co-culture biofilms formed by Staphylococcus aureus and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 2011; 62: 339-347.
95. Hammer ND, Skaar EP. Molecular mechanisms of Staphylococcus aureus iron acquisition. Ann Rev Microbiol 2011; 65: 129-147.
96. Morton DJ, Turman EJ, Hensley PD, et al. Identification of a siderophore utilization locus in nontypeable Haemophilus influenzae. BMC Microbiol 2010; 10: 113.
97. Peeters E, Nelis HJ, Coenye T. Resistance of planktonic and biofilm-grown Burkholderia cepacia complex isolates to the transition metal gallium. J Antimicrob Chemother 2008; 61: 1062-1065.
98. Lechuga-Ballesteros D, Truong-Le V, Patzer EJ. Comment on: Resistance of planktonic and biofilm-grown Burkholderia cepacia complex isolates to the transition metal gallium. J Antimicrob Chemother 2009; 63: 1078-1079.
99. Baldoni D, Steinhuber A, Zimmerli W, et al. In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods. Antimicrob Agents Chemother 2010; 54: 157-163.
100. Percival SL, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect Control Hospital Epidemiol 2005; 26: 515-519.
101. Al-Azemi A, Fielder MD, Abuknesha RA, et al. Effects of chelating agent and environmental stresses on microbial biofilms: relevance to clinical microbiology. J Appl Microbiol 2011; 110: 1307-1313.
102. Aguila A, Herrera AG, Morrison D, et al. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunol Med Microbiol 2001; 31: 145-152.
103. Kim CM, Shin SH. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J Korean Med Sci 2009; 24: 289-295.
104. Sebulsky MT, Heinrichs DE. Identification and characterization of fhuD1 and fhuD2, two genes involved in ironhydroxamate uptake in Staphylococcus aureus. J Bacteriol 2001; 183: 4994-5000.
105. VanDevanter DR, Van Dalfsen JM. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? Pediatr Pulmonol 2005; 39: 504-506.
106. Guilbault C, Saeed Z, Downey GP, et al. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007; 36: 1-7.
107. Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 2011; 10: Suppl. 2, S152-S171.
108. Coleman FT, Mueschenborn S, Meluleni G, et al. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci USA 2003; 100: 1949-1954.
109. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010; 2: 29ra31.
110. Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010; 120: 3149-3160.